BDF
PDLI

Balasa Dinverno & Foltz’s PDL BioPharma, Inc. PDLI Stock Holding History

Balasa Dinverno & Foltz’s Portfolio PDLI Stock Details PDLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-86,988
Closed -$559K – 218
2015
Q2 		$559K Buy
86,988
+57,116
+191% +$383K 0.09% 78
2015
Q1 		$210K Buy
+29,872
New +$216K 0.03% 193

Other funds holding PDLI

ACM
Americafirst Capital Management Roseville, California $74M AUM 13.49% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
GAM
Gotham Asset Management New York $32.7B AUM 27.65% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
AAM
Advisors Asset Management Monument, Colorado $6.01B AUM 24.74% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Balasa Dinverno & Foltz's PDLI Position: Q3 2015 in Review

Balasa Dinverno & Foltz sold out of PDL BioPharma, Inc. (PDLI) in Q3 2015, closing a stake of 86,988 shares — an estimated $559K sold.

Balasa Dinverno & Foltz first reported a position in PDLI in Q1 2015 and held it in 2 quarters. The position peaked at $559K in Q2 2015. 213 funds tracked by Wall St. Rank hold PDLI as of Q3 2015.

  • Balasa Dinverno & Foltz reported no remaining PDL BioPharma, Inc. position as of Q3 2015 after selling out during the quarter.
  • Balasa Dinverno & Foltz sold 86,988 PDL BioPharma, Inc. shares in Q3 2015, an estimated $559K.
  • Balasa Dinverno & Foltz first reported a position in PDL BioPharma, Inc. in Q1 2015 and held it in 2 quarters.
  • Balasa Dinverno & Foltz's PDL BioPharma, Inc. position peaked at $559K in Q2 2015.
  • 213 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q3 2015.

Based on Balasa Dinverno & Foltz's 13F filing for Q3 2015, filed 9 Nov 2015.